Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with bullous pemphigoid~* Stable dose of prednisone at or above 10mg per day but no greater than 1 mg/kg/day~* Weigh between 40-120kg~* total IgE level up to 5000 IU/mL~Exclusion Criteria:~* Use of rituximab within 1 year~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 (Type: EXPERIMENTAL): QGE031 240 mg Q2W s.c.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Match Q2W s.c.
- Open Label QGE031 (Type: EXPERIMENTAL): Open Label QGE031 Q2W s.c.

Based on this trial design, predict the completion outcome and termination type (if applicable).